Kymriah and the Outcomes-Based Contract: Is this a Trend?

Is the outcomes based contract agreed for Kymriah the beginning of a trend? The one-time drug has a hefty price tag of $475,000, but Novartis will only receive payment from CMS if patients show significant improvement. Are these contracts a good way of sharing risk and ensuring wider access to novel therapies?